HOME >> BIOLOGY >> NEWS
48-wk resistance data comparing GW433908 boosted & unboosted with nelfinavir

Boston (Feb. 11, 2003) Forty-eight-week data were presented here today from two Phase III studies (NEAT and SOLO) of treatment-nave patients with HIV infection, evaluating the resistance profile of the investigational protease inhibitor (PI) GW433908 (908) dosed twice a day (BID) or 908 boosted with the PI ritonavir (908/r) dosed once a day (QD) compared to the PI nelfinavir (NFV) BID. The medications in both studies were administered as part of combination therapy that also included 300 mg abacavir (ABC) BID and 150 mg lamivudine (3TC) BID. ABC and 3TC are nucleoside reverse transcriptase inhibitors (NRTIs).

908 is the calcium phosphate ester pro-drug of amprenavir (APV) and was co-discovered by GlaxoSmithKline (GSK) and Vertex Pharmaceuticals (Nasdaq: VRTX). In the SOLO study, no patients (0 percent) in the 908/r arm, out of 32 subjects experiencing virologic failure or with ongoing viral replication, had detectable primary or secondary PI mutations. In contrast, 27 of 54 patients (50 percent) in the NFV arm developed primary or secondary PI mutations. The clinical relevance of the resistance data is currently under evaluation.

In the NEAT study, 5 of 29 patients (17 percent) who experienced treatment failure in the unboosted 908 arm had mutations characteristic of APV resistance. NFV-selected mutations were observed in 7 of 26 patients (27 percent) who experienced virologic failure in the nelfinavir arm.

In the NEAT study, mutations selected by 908 were consistent with the spectrum of mutations selected by APV. Mutations detected in patients taking unboosted 908 included I54L/M, M46I and V32I+I47V. Mutations observed with other PIs (D30N, I54V, V82A/T/S, L90M) were not detected among patients taking unboosted 908.

In the SOLO study, there was a statistically significant difference between 908/r QD and NFV BID in the incidence of treatment emergent mutations selected by either the study PI (P<0.001) or the NRTIs ABC and
'"/>

Contact: Amy Kling
akling@pcipr.com
312-558-1770
Public Communications Inc.
11-Feb-2003


Page: 1 2 3

Related biology news :

1. Master of antimalarial resistance
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Evolvability could be a driving force in drug resistance
4. Insecticide resistance: A constraint on evolutionary change
5. New drug shows promise against Gleevec resistance in mice
6. New milestones on the path to conquering HIV drug resistance (AIDS)
7. Study investigates breast cancer resistance to tamoxifen and possible way to reverse it
8. Antibiotic resistance risk from triclosan questioned
9. Cancer drug resistance research leads to possible therapeutic target for Alzheimers disease
10. Researchers string together players in pesticide resistance orchestra
11. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/14/2019)... ... 14, 2019 , ... IMMUNE 3D®, a privately held biotechnology ... of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its ... efforts. , IMMUNE 3D®’s proprietary platform aims to study factors that affect ...
(Date:5/8/2019)... ... May 08, 2019 , ... RG+A, Inc., ... Carol S. Mann has agreed to serve as Chief Executive Officer and pharmaceutical ... Officer, effective immediately. They will join Chairman and Founder Roger Green to create ...
(Date:5/7/2019)... ... May 07, 2019 , ... ... Beach Convention and Entertainment Center from May 15- 17. At booth #226, AMGtime ... These include flexible software, biometric hardware, mobile apps, specialized industry solutions, advanced add-on ...
Breaking Biology News(10 mins):
(Date:5/2/2019)... ... May 02, 2019 , ... Boston Robotic Hair ... area. Gone are the days of painful hair transplant procedures. Boston Robotic Hair ... is the only robotic intelligent solution to offer a minimally invasive procedure. With ...
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Agents for sales and service organizations, today announced global availability of Inference ... providers and enterprises of all sizes to harness the power of Google’s ...
(Date:4/16/2019)... Md. (PRWEB) , ... April 16, 2019 , ... ... honor Blue Sources and their project partner, the U.S. Army Center for Environmental ... of Aquatic Biomonitor Through Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located ...
(Date:4/15/2019)... ... 2019 , ... Sirrus, Inc., a developer of novel electron-deficient ... to increase production of methylene malonate monomers and oligomers. , The expanded bench ... production facility, which is scheduled to break ground in 2019. “The expanded facility ...
Breaking Biology Technology:
Cached News: